Mawatari, Go
Fujinami, Kaoru
Liu, Xiao
Yang, Lizhu
Yokokawa, Yu-Fujinami
Komori, Shiori
Ueno, Shinji
Terasaki, Hiroko
Katagiri, Satoshi
Hayashi, Takaaki
Kuniyoshi, Kazuki
Miyake, Yozo
Tsunoda, Kazushige
Yoshitake, Kazutoshi
Iwata, Takeshi
Nao-i, Nobuhisa
,
Article History
Received: 14 March 2019
Revised: 21 May 2019
Accepted: 30 June 2019
First Online: 2 August 2019
Change Date: 10 February 2020
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Conflict of interest
: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor but may receive salary or other support from the institution to support their effort on the project(s). Kaoru Fujinami is a paid consultant of Astellas Pharma Inc., Kubota Pharmaceutical Holdings Co., Ltd, Acucela Inc., Novartis AG., and NightstaRx Limited. Kaoru Fujinami reports personal fees from Astellas Pharma Inc., Kubota Pharmaceutical Holdings Co., Ltd., Acucela Inc., Novartis AG., SANTEN Company Limited, the Foundation Fighting Blindness, the Foundation Fighting Blindness Clinical Research Institute, the Japanese Ophthalmology Society, and the Japan Retinitis Pigmentosa Society. The laboratory of Visual Physiology, Division for Vision Research, National Institute of Sensory Organs, National Hospital Organization, Tokyo Medical Center, Tokyo, Japan is supported by grants from Astellas Pharma Inc. (NCT03281005), outside the submitted work.